Explore every episode of the podcast MedEdTalks - Gastroenterology
| Title | Pub. Date | Duration | |
|---|---|---|---|
| Diet and Targeted Therapy With Drs. Dellon and Hirano | 19 May 2023 | 00:30:25 | |
In this podcast, expert clinicians will discuss diet considerations and targeted therapy for treatment of EoE. | |||
| Steroids and PPIs in the Treatment of EoE With Drs. Dellon and Beveridge | 19 May 2023 | 00:22:48 | |
In this podcast, expert clinicians will discuss the role of steroids and PPIs for treatment of EoE. | |||
| Differential Diagnosis of EoE With Drs. Dellon and Chehade | 19 May 2023 | 00:26:11 | |
In this podcast, expert clinicians will discuss best practices for the differential diagnosis of EoE. | |||
| Pearls From the Pros on IBD Management: Anti-Integrin and S1P Receptor Modulation in IBD Practice With Drs. David Rubin and Maria Abreu | 06 Jan 2022 | 00:24:58 | |
In this podcast, expert clinicians discuss the latest updates on anti-integrin therapy and S1P receptor modulators in IBD management. | |||
| Pearls From the Pros on IBD Management: JAK Inhibition in IBD Practice With Drs. David Rubin and Millie Long | 06 Jan 2022 | 00:21:07 | |
In this podcast, expert clinicians discuss the latest updates on JAK inhibition in IBD management. | |||
| Pearls From the Pros on IBD Management: Anti-IL-12/23 in IBD Practice With Drs. David Rubin and Bruce Sands | 06 Jan 2022 | 00:16:34 | |
In this podcast, expert clinicians discuss the latest updates on anti-IL-12/23 therapy in IBD management. | |||
| Pearls From the Pros on IBD Management: Anti-TNF Therapy in IBD Practice With Drs. David Rubin and Stephen Hanauer | 06 Jan 2022 | 00:22:22 | |
In this podcast, expert clinicians discuss the latest updates on anti-TNF therapy in IBD management. | |||
| Immunogenicity of Current IBD Biologics With Drs. Edward Loftus and Marla Dubinsky | 18 Aug 2021 | 00:13:25 | |
In this podcast, expert clinicians compare the immunogenicity of available biologic therapies and explore options for managing patients who develop anti-drug antibodies. | |||
| Extraintestinal Manifestations of IBD With Drs. Edward Loftus and Miguel Regueiro | 18 Aug 2021 | 00:10:36 | |
In this podcast, expert clinicians review the variety of extraintestinal manifestations seen in patients with IBD, discussing strategies for assessment and management. | |||
| Biologics for IBD – Monotherapy Versus Combination Approaches With Drs. Edward Loftus and Marla Dubinsky | 18 Aug 2021 | 00:14:30 | |
In this podcast, experts review appropriate applications of monotherapy and combination therapy and how to position particular therapies based on disease and patient characteristics. | |||
| New Insights on Treat to Target in Moderate to Severe IBD With Drs. Edward Loftus and Miguel Regueiro | 18 Aug 2021 | 00:15:19 | |
In this podcast, expert clinicians will discuss the shift from symptom-based management to a treat-to-target paradigm, detailing important treatment aims and reviewing the mechanisms of action of available therapies. | |||
| Efficacy and Safety of Anti-interleukin (IL) 23 and Janus Kinase (JAK) Inhibitors with Drs. William J. Sandborn and Jessica R. Allegretti | 16 Mar 2021 | 00:16:48 | |
In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-IL-23 and JAK inhibitors, that are in late-stage development for treating moderate to severe CD. | |||
| Efficacy and Safety of Anti-integrin and Sphingosine-1-Phosphate (S1P)-1 Receptor Modulators with Drs. Bruce E. Sands and William J. Sandborn | 16 Mar 2021 | 00:15:37 | |
In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-integrin and S1P-1 receptor modulators, that are in late-stage development for treating moderate to severe CD. | |||
| Mechanisms of Action of New Classes of Agents for Moderate to Severe Crohn’s Disease with Drs. William J. Sandborn and Bruce E. Sands | 16 Mar 2021 | 00:19:34 | |
In this podcast, expert clinicians will discuss emerging therapies with unique mechanisms of action that can improve the treatment of moderate to severe Crohn’s disease. | |||
| Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 Inhibitors | 29 Apr 2019 | 00:12:25 | |
Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 InhibitorsInflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed. In this CME podcast activity, Dr. Peter Higgins and Dr. David Rubin will discuss investigational interleukin-12 and interleukin-23 inhibitors for treating UC. For the transcript of this podcast, click here. To obtain CME credit, click here | |||
| Investigational Agents in Ulcerative Colitis: JAK Inhibitors and S1P Receptor Modulators | 29 Apr 2019 | 00:09:12 | |
Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed. In this CME podcast activity, Dr. Peter Higgins and Dr. William Sandborn will discuss investigational Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators for treating UC. For the transcript of this podcast, click here. To obtain CME credit, click here | |||
| Investigational Agents in Ulcerative Colitis: Anti-Integrins | 25 Apr 2019 | 00:09:37 | |
Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed. In this CME podcast activity, Dr. David Rubin and Dr. Peter Higgins will discuss investigational anti-integrin therapies for UC. For the transcript of this podcast, click here To obtain CME credit, click here | |||
| Ulcerative Colitis: Targeting Immunological Pathways in Moderate to Severe Disease – Updates From Copenhagen | 25 Apr 2019 | 00:00:48 | |
Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed. In this CME podcast activity, expert physicians will discuss investigational UC therapies with various mechanisms of action. For the full CME activity, click here | |||